Lucinda Billingham
- Oncology top 1%
- Lung Cancer Research Studies 8
-
- Lung Cancer Treatments and Mutations 23
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 16
- Internal Medicine top 5%
- Immunology top 5%
-
- Statistical Methods in Clinical Trials 21
-
- Health Systems, Economic Evaluations, Quality of Life 17
-
- Bladder and Urothelial Cancer Treatments 9
-
- Lymphoma Diagnosis and Treatment 8
-
- Advanced Proteomics Techniques and Applications 7
- Co-authors
- Keith R. AbramsNeil StevenStirling BryanM.H. CullenDaniel ReaRichard T. BryanD. Michael A. WallacePhilip J. Johnson
- Partner nations
- United KingdomUnited StatesNetherlands
In The Last Decade
Lucinda Billingham
131 papers receiving 4.9k citations
Peers
Comparison fields: 5 of 152
- Oncology 2.1k
- Pulmonary and Respiratory Medicine 1.2k
- Cancer Research 512
- Internal Medicine 123
- Immunology 475
Countries citing papers authored by Lucinda Billingham
This map shows the geographic impact of Lucinda Billingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lucinda Billingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lucinda Billingham more than expected).
Fields of papers citing papers by Lucinda Billingham
This network shows the impact of papers produced by Lucinda Billingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lucinda Billingham. The network helps show where Lucinda Billingham may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Lucinda Billingham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 14 | |
| 2 | 2024 | 2 | |
| 3 | 2023 | 1 | |
| 4 | 2023 | 4 | |
| 5 | 2023 | 5 | |
| 6 | 2023 | 1 | |
| 7 | 2022 | 4 | |
| 8 | 2022 | 9 | |
| 9 | 2019 | 1 | |
| 10 | 2017 | 21 | |
| 11 | 2017 | 15 | |
| 12 | 2017 | 17 | |
| 13 | 2016 | 21 | |
| 14 | 2014 | 15 | |
| 15 | 2012 | 5 | |
| 16 | 2007 | 0 | |
| 17 | 2003 | 39 | |
| 18 | Mitomycin,Ifosfamide and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life | 2001 | 6 |
| 19 | Methods for the analysis of quality-of-life and survival data in health technology assessment. | 1999 | 248 |
| 20 | Quality assurance of CD34+ cell estimation in leucapheresis products. | 1996 | 22 |
About Lucinda Billingham
Lucinda Billingham is a scholar working on Statistics and Probability, Oncology and Cancer Research, having authored 138 papers that have together received 5.0k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (23 papers), Statistical Methods in Clinical Trials (21 papers), Health Systems, Economic Evaluations, Quality of Life (17 papers), Cancer Genomics and Diagnostics (16 papers), Bladder and Urothelial Cancer Treatments (9 papers), Lymphoma Diagnosis and Treatment (8 papers), Lung Cancer Research Studies (8 papers) and Advanced Proteomics Techniques and Applications (7 papers). The work is most often cited by research in Oncology (2.1k citations), Pulmonary and Respiratory Medicine (1.2k citations) and Cancer Research (512 citations). Lucinda Billingham has collaborated with scholars based in United Kingdom, United States and Netherlands. Frequent co-authors include Keith R. Abrams, Neil Steven, Stirling Bryan, M.H. Cullen, Daniel Rea, Richard T. Bryan, D. Michael A. Wallace, Philip J. Johnson, Andrea Burton and K Malottki. Their work appears in journals such as Journal of Clinical Oncology, Trials, Lung Cancer, British Journal of Cancer and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.